Eppe obesity drug price in Korea starts near half of Mounjaro as Hanmi launches October 29

The Eppe obesity drug price undercuts both imported leaders in South Korea from the first month. Hanmi Pharmaceutical plans to make Eppe, the first GLP 1 obesity injection developed in Korea, available by prescription at selected clinics around October 29. Industry figures put the first month at 129,800 won including VAT, roughly half of what a month of Mounjaro costs at its lowest dose. Here is the month by month price, how it compares, and what is still unclear.

The month by month price

Herald Corp reported the price ladder on October 15, citing industry sources, with VAT included. The first month costs 129,800 won, made up of two boxes of two pens each at the starting strengths. The second month costs 228,800 won and the third 277,200 won, as the patient moves up through higher strengths sold in boxes of four pens. From the fourth month, the maintenance strength costs 299,200 won a month. The report added that the final amount a patient pays may still differ, because wholesale margins and the prices set by each clinic or pharmacy can move the figure. In other words, these are reference prices, and the counter price will vary.

The step pattern matters for anyone budgeting a year of care. Using the reported figures, the first three months add up to 635,800 won. Every month after that adds 299,200 won, so a full first year at the maintenance strength would come to about 3.33 million won before clinic fees and tests. That is a rough sum built from the published reference prices, not a quote, and it assumes a patient stays on the plan for all twelve months. Many people stop or pause treatment, and some stay at a lower strength. Even so, the arithmetic shows that the Eppe obesity drug price advantage is largest at the start and narrows once both rivals and Eppe reach their maintenance steps.

How Eppe compares with Wegovy and Mounjaro

At the start, the gap is wide. According to Herald Corp, the first month of Eppe is 37 percent cheaper than Wegovy and 53 percent cheaper than Mounjaro. Korea Biomedical Review, citing Yonhap news agency, put the first month supply price at about 130,000 won, against about 270,000 won for four weeks of Mounjaro at its lowest dose and slightly over 200,000 won for Wegovy, according to local reports. At maintenance, the difference shrinks. Herald Corp put Eppe at about 17 percent below Wegovy and 19 percent below Mounjaro once each drug reaches its regular monthly strength. So the saving is real over a year, but it is smaller than the headline starting price suggests.

So the saving is real over a year, but it is smaller than the headline starting price suggests.

Price is only half of the comparison. In interim results from a Phase 3 trial in 448 Korean adults, people on Eppe lost an average of 9.75 percent of their body weight over 40 weeks, Korea Biomedical Review reported. Separate trials of Wegovy and Mounjaro have reported average losses of roughly 15 to 20 percent, though different trial groups and designs make a direct comparison unreliable. For a patient, that means the cheaper drug may also produce less weight loss on average, and the right choice depends on medical history, goals and what a doctor advises. The approval covers adults with obesity, or with overweight and no diabetes, alongside diet and exercise, and the drug is a once weekly injection.

Who pays for Eppe

For now, patients do. Herald Corp described the imported rivals as uninsured, and it presented the Eppe figures as amounts patients will pay, which points to out of pocket spending rather than national health insurance cover. Neither report said whether Hanmi plans to seek reimbursement. That makes the Eppe obesity drug price the main access lever. Korea's market for obesity drugs is estimated at about 2 trillion won, Herald Corp reported, and a lower entry price could draw in people who found the imported pens too costly. It also gives clinics a cheaper option to offer to patients who want to try treatment before committing to a higher monthly bill. Our price desk tracks how such entry prices move once competitors respond.

Prescribers will face new questions at the first visit. A patient may ask for the cheapest pen, while the evidence suggests the imported drugs produce more weight loss on average. That is a medical decision as much as a financial one, and the reported figures do not settle it. Pharmacies that dispense Eppe will need to stock several box sizes for the first three months, since each strength comes in its own pack. Rival makers may respond on price, though neither Novo Nordisk nor Eli Lilly has said anything public about Korean prices in the reports we checked. For now, the reference prices are the only public benchmark, and patients may want to compare the quote from more than one clinic.

Home grown supply and the launch date

Eppe is also a supply story. Hanmi plans to make the drug entirely at its Pyeongtaek Bio Plant, covering both the active ingredient and the finished pens, according to Korea Biomedical Review. Domestic production means this product does not depend on imported pens, although the company has not published how many pens the plant can produce. The Ministry of Food and Drug Safety approved Eppe in early October as Korea's 45th new drug, Herald Corp reported. Hanmi set the October 29 date at a symposium for health professionals in Seoul. The table shows the reported prices and how they compare at each stage of treatment.

Hanmi has framed the launch in strategic terms. "Eppe is more than just another GLP 1 obesity treatment entering the market," vice chair Lim Ju-hyun said, according to The Korea Herald. For readers, the practical points about the Eppe obesity drug price are narrower. The first month is cheap, the gap shrinks later, the drug needs a prescription, and the price at a given clinic may differ from the reference figures. Patients should obtain it only through a clinic and pharmacy, not from online sellers or social media posts, where counterfeit and badly stored pens are a known risk. Follow our supply reporting for how the Pyeongtaek plant and imported pens keep up with demand once the launch is under way.

Conclusion

The Eppe obesity drug price starts at 129,800 won for the first month and rises to 299,200 won a month at maintenance, according to industry figures, about half of Mounjaro at the start but only around a fifth cheaper later. Eppe reaches selected clinics around October 29 by prescription. Ask your doctor whether it fits your goals before comparing prices.